Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 119, Issue 12, Pages -Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2122310119
Keywords
pH-degradable nanogel; macrophage repolarization; bisphosphonate; drug delivery; fibrosis
Categories
Funding
- German Research Foundation [(CRC/SFB) 1066]
- German Research Foundation through the Emmy Noether program
Ask authors/readers for more resources
In this study, liver fibrosis progression was prevented by repolarizing M2-type macrophages towards a non-fibrotic phenotype using a pH-degradable nanogel carrier system. The nanogels efficiently delivered the drug alendronate to nonparenchymal cells of fibrotic livers, reprogramming profibrotic M2 into antifibrotic M1 macrophages and preventing liver fibrosis progression. This approach has potential implications for the treatment of diseases driven by M2-type macrophages, including cancer.
Immune-suppressive (M2-type) macrophages can contribute to the progression of cancer and fibrosis. In chronic liver diseases, M2-type macrophages promote the replacement of functional parenchyma by collagen-rich scar tissue. Here, we aim to prevent liver fibrosis progression by repolarizing liver M2-type macrophages toward a non fibrotic phenotype by applying a pH-degradable, squaric ester-based nanogel carrier system. This nanotechnology platform enables a selective conjugation of the highly water-soluble bisphosphonate alendronate, a macrophage-repolarizing agent that intrinsically targets bone tissue. The covalent delivery system, however, promotes the drug's safe and efficient delivery to nonparenchymal cells of fibrotic livers after intravenous administration. The bisphosphonate payload does not eliminate but instead reprograms profibrotic M2-toward antifibrotic M1-type macrophages in vitro and potently prevents liver fibrosis progression in vivo, mainly via induction of a fibrolytic phenotype, as demonstrated by transcriptomic and proteomic analyses. Therefore, the alendronateloaded squaric ester-based nanogels represent an attractive approach for nano therapeutic interventions in fibrosis and other diseases driven by M2-type macrophages, including cancer. Significance Fibrosis is a consequence of most chronic liver diseases, but currently no approved antifibrotic treatment is available. M2-type macrophages drive fibrosis progression and prevent regression, even when effective causal therapies have been employed. M2-type macrophages activate a cascade of fibrogenic effector cells and can prevent removal of excess scar tissue. To switch these profibrogenic M2 to fibrolytic (regenerative) macrophages, we developed a pH-degradable, nanogel-based delivery system which can be covalently functionalized with the macrophage-repolarizing bisphosphonate alendronate. The nanogels efficiently deliver the clinically approved drug into hepatic nonparenchymal cells after intravenous administration. They do not eliminate macrophages but repolarize their phenotype and subsequently block fibrosis progression. This approach establishes a nanotherapeutic delivery platform to treat further M2-type macrophage-driven diseases, including cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available